CEL-SCI Corporation
CVMHealthcare|Biotechnology|US
$1.45
+0.08 (+5.84%)
DCF Value
$0.21
Tangible Book / Share
$0.90
Cash / Share
$0.54
Analyst Consensus
Buy6 analysts
Strong Buy
0
Buy
6
Hold
0
Sell
0
Strong Sell
0
Rating Trend
Dec 25
2 buy · 0 hold · 0 sell
Jan 26
2 buy · 0 hold · 0 sell
Feb 26
2 buy · 0 hold · 0 sell
Mar 26
1 buy · 0 hold · 0 sell
Apr 26
1 buy · 0 hold · 0 sell
May 26
1 buy · 0 hold · 0 sell
Jun 26
1 buy · 0 hold · 0 sell
Jul 26
1 buy · 0 hold · 0 sell
Aug 26
2 buy · 0 hold · 0 sell
Sep 26
2 buy · 0 hold · 0 sell
Oct 26
2 buy · 0 hold · 0 sell
Nov 26
2 buy · 0 hold · 0 sell
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| EF Hutton | maintain | Buy | Jul 12, 2023 |
| EF Hutton | maintain | Buy | Mar 9, 2023 |
| EF Hutton | maintain | Buy | Dec 29, 2022 |
| EF Hutton | maintain | Buy | Aug 25, 2022 |
| EF Hutton | maintain | Buy | Apr 7, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jan 13, 2020 |
| H.C. Wainwright | maintain | Buy | Jan 13, 2020 |
| Taglich Brothers | maintain | Speculative Buy →Buy | Feb 20, 2013 |
| Chardan Capital | maintain | Buy | Feb 13, 2013 |
| Laidlaw & Co. | maintain | Buy | Jan 14, 2013 |
Earnings History
Next report: Dec 23, 2026| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.47 | — | — | — |
| May 18, 2026 | $-0.67 | — | — | — |
| Feb 17, 2026 | $-0.68 | — | — | — |
| Dec 29, 2025 | $-0.76 | — | — | — |
| Aug 14, 2025 | $-1.36 | — | — | — |
| May 14, 2025 | $-2.40 | — | — | — |
| Feb 12, 2025 | $-3.30 | — | — | — |
| Jan 13, 2025 | $-3.07 | $-0.11 | — | — |
News
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
VIENNA, Va,--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival.
Oct 26, 2026businesswire.com
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.
Sep 15, 2026businesswire.com
CEL-SCI Reports Fiscal Third Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
Aug 17, 2026businesswire.com